Apex Biotechnology

Apex Biotechnology EBIT Margin

The EBIT Margin (Operating Margin) of Apex Biotechnology (1733.TW) as of Nov 22, 2026 is 7.24 %. In the previous year, EBIT Margin (Operating Margin) was 6.94 % — a change of 4.29% (higher).

EBIT Margin

7.24 %

YoY

4.29%

Last updated:

EBIT Margin (Operating Margin) of Apex Biotechnology is 2025 7.24 % . EBIT Margin (Operating Margin) of Apex Biotechnology was 2024 6.94 % . It decreases by 4.29% higher compared to the previous year.

For Apex Biotechnology, the operating (EBIT) margin of 7.2% is down versus 9.1% a few years ago.

The Apex Biotechnology EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
11.12 TWD
Jan 1, 2019
7.86 TWD
Jan 1, 2020
6.01 TWD
Jan 1, 2021
9.10 TWD
Jan 1, 2022
9.13 TWD
Jan 1, 2023
8.45 TWD
Jan 1, 2024
6.94 TWD
Jan 1, 2025
7.24 TWD
The Apex Biotechnology EBIT Margin history
YEAREBIT MarginYoY
7.24 %+4.29%
6.94 %-17.92%
8.45 %-7.45%
9.13 %+0.37%
9.10 %+51.40%
6.01 %-23.57%
7.86 %-29.32%
11.12 %+24.05%
8.97 %-35.69%
13.94 %-14.35%
16.28 %+0.61%
16.18 %+8,381.80%
0.19 %-35.85%
0.30 %+0.07%
0.30 %-9.41%
0.33 %+5.03%
0.31 %+3.23%
0.30 %-24.36%
0.40 %+28.09%
0.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apex Biotechnology Stock analysis

What does Apex Biotechnology do? Apex Biotechnology Corp is a Taiwan-based company specializing in the development of innovative biotechnology products. The company was founded in 2002 and offers a wide range of products and services to its customers. Apex Biotechnology Corp began with the production of specialty chemicals and enzymes for research and development purposes. Over the years, the company has expanded its business and focused on the development of diagnostic products, dietary supplements, and pharmaceutical products. The company's business model focuses on the development and marketing of biotechnology products. Apex Biotechnology Corp has established advanced research centers and works closely with research institutions and pharmaceutical companies worldwide to develop innovative solutions. The company operates in various sectors, including diagnostics, dietary supplements, and pharmaceuticals. It offers a diverse range of products, including enzyme immunoassays, lateral flow tests, dietary supplements, and pharmaceuticals. Apex Biotechnology Corp has built strong relationships with research institutions and pharmaceutical companies and has successfully marketed its products internationally. Apex Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apex Biotechnology stock

EBIT Margin (Operating Margin) of Apex Biotechnology is 7.24 % in 2025.

EBIT Margin (Operating Margin) of Apex Biotechnology changed from 6.94 % to 7.24 %, representing a 4.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Apex Biotechnology since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Apex Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Apex Biotechnology

All Key Metrics — Apex Biotechnology